BioMarin BMRN Earnings Analysis

Earnings Analysis of BMRN Over the Last Three Years

1. Revenue Analysis

Total and Operating Revenue: Over the provided periods, BMRN’s total revenue shows a varying trend with amounts of $595.3 million (2023-06), $596.4 million (2023-03), $581.3 million (2023-09), $646.2 million (2023-12), and $648.8 million (2024-03). Operating Revenue directly corresponds to Total Revenue for all recorded periods.

Gross Profit: Gross Profit has seen a slight fluctuation starting from $467.2 million in 2023-06, increasing to $523.7 million by 2024-03. This reflects efficiency or changes in cost of sales or service provisioning.

2. Cost Management

Cost of Revenue: Cost of Revenue has hovered around $118 million to $135 million up until 2023-06, showing a slight increase in the subsequent quarters up to $125.2 million in 2024-03. This reflects relatively stable direct costs associated with revenue generation.

Operating Expense: Operating Expenses peaked at $496.5 million in 2023-12 before dropping to $445.2 million in 2024-03. This may imply cost reduction strategies or seasonal variabilities.

Total Expenses: These remained high, averaging upwards of $531 million, topping at $631.9 million in 2023-12, showing significant operational expenditure.

3. Profitability Analysis

EBITDA: EBITDA increased from $71.1 million in 2023-09 to $136.4 million in 2024-03, indicating improving earnings before interest, taxes, depreciation, and amortization.

Operating Income: Starting from $58.9 million in 2023-06 and increasing to $78.5 million in 2024-03, BMRN has shown improvement in operating performance.

Pretax Income: Pretax Income showed growth from $56.8 million in 2023-03 to $105.5 million in 2024-03, demonstrating growth in income before tax over these periods.

Net Income: Net Income metrics exhibit significant variability, peaking at $88.7 million most recently in 2024-03 from earlier values around $20 million to $56 million, indicating fluctuating profitability after all adjustments and tax considerations.

4. Cash Flow Indicators

Reconciled Depreciation: There are modest changes, consistently about $26-27 million per quarter. Depreciation is a non-cash charge which moderately impacts the cash flow.

Interest Expense: Ranges from $3.7 million to $5.5 million up until the most recent quarter at $3.5 million, showing BMRN is managing similar levels of debt costs.

5. Taxation

Tax Rate: The effective tax rate has seen variations, noteworthy is the high of 0.21 in 2023-12 from a low of 0.03 in 2023-09.

Tax Provision: Fluctuated from a high $14.8 million in 2023-06 to recovery of ($1.0 million) in 2023-12. This shows periods of different profit levels and corresponding tax provisions.

Tax Effect of Unusual Items: Noticed only in 2024-03 with a value around $1.6 million, which could be linked to specific non-recurring transactions.

6. Shareholder Metrics

Diluted and Basic EPS: Earnings Per Share (EPS) has seen an increase, with Diluted EPS climbing from 0.27 in 2023-03 to 0.46 in 2024-03. This mirrors Basic EPS growth, thereby benefiting shareholders.

Average Shares: Average shares outstanding appears relatively stable, showing a small increase over time which may dilute individual share value.

Net Income Available to Common Stockholders: This mirrors the Net Income metrics, highlighting the direct benefit to stockholders.

7. Conclusion

In conclusion, BMRN has shown significant signs of growth and improvement in many aspects of their financial health from revenue growth, cost management, and profitability. The tax rate and provisions indicate a complex fiscal environment which they have navigated with varying degrees of success. For investors, BMRN presents a potentially attractive investment opportunity based on improving performance metrics, reflected particularly in the growth of Net Income and EPS.